Cellbion's Next Strategy: From ARC to Combination with MSD's∙∙∙

CellBion Announces Clinical Trial Collaboration with MSD to ∙∙∙

CellBion Announces Clinical Trial Collaboration with MSD to ∙∙∙

Cellbion, Prostate Cancer Treatment Drug ORR Significantly E∙∙∙

Kim Kwon, CEO of Cellvion, said, "I am confident in developi∙∙∙

[IPO Analysis] Cellbion Passes Listing Review in Just Three ∙∙∙

Cellbion Submits Securities Registration Statement, Accelera∙∙∙

Cellbion Submits Securities Registration Statement for KOSDA∙∙∙

Cellbion Submits Securities Registration Statement, Initiate∙∙∙

Cellbion Prepares for KOSDAQ Listing, Submits Securities Reg∙∙∙

Radiopharmaceutical Company Cellbion∙∙∙

Cellbion Initiates IPO Process, Files Securities Registratio∙∙∙

Venture Business Association Announces the ‘2024 Excellent V∙∙∙

Cellbion, Developer of Radioactive Pharmaceuticals, Receives∙∙∙

Cellbion, Developer of 'RPT', Receives Approval for Kosdaq P∙∙∙

Cellbion Clears Listing Hurdle, Kosdaq Preliminary Review Ap∙∙∙

KOSDAQ Market Division of Korea Exchange Announces Approval ∙∙∙

Cellbion, a Radiopharmaceutical Company, Passes Preliminary ∙∙∙

‘Competition with Fluvicto’ Cellbion takes on the best chall∙∙∙

Aptis and CellBion sign MOU for development of next-generati∙∙∙